KIT and gastrointestinal stromal tumor: Previous studies have revealed that inhibiting Wee1 G2 checkpoint kinase (Wee1) promotes autophagic degradation of KIT, suggesting that targeting Wee1 could offer a novel therapeutic strategy for GIST [14].